ResMed Inc. (RMD) Investor Relations Documents

ResMed Inc. (RMD) investor relations documents from the company's IR site: 15 presentations, 24 press releases; latest deck 2026-04-30. Read in-app with summaries. First-party data.

PresentationPDF — ResMed Q3 FY26 earnings report highlights $5.5B LTM revenue and the $340M acquisition of Noctrix to expand its sleep health portfolio into Restless Leg Syndrome.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-17Press releaseResmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
2026-08-06Press releaseResmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
2026-07-07Press releaseResmed Announces Agreement to Sell MatrixCare Business
2026-06-30Press releaseResmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
2026-06-01Press releaseResmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
2026-05-19Press releaseResmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
2026-05-19Press releaseResmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
2026-04-30Press releaseResmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
2026-04-30Earnings deckPresentationPDF
2026-04-30Press releaseEarnings ReleaseHTML
2026-04-01Press releaseResmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
2026-03-03Press releaseResmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach
2026-01-29Earnings deckQ2 FY26 Earnings Presentation
2026-01-12PresentationJPM 2026 Healthcare Conference Presentation
2026-01-08Press releaseResmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026
2025-12-16ESG reportModern Slavery and Human Trafficking Statement Download
2025-10-30Earnings deckPresentationPDF
2025-10-09Press releaseResmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025
2025-08-27Press releaseObstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
2025-08-21Press releaseResmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs
2025-07-31Earnings deckPresentationPDF
2025-07-31PresentationCorporate 1-PagerPDF
2025-07-31Press releaseResmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025
2025-07-01Press releaseResmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025
2025-06-04PresentationWilliam Blair Growth Stock Conference Presentation
2025-04-23PresentationCorporate 1-PagerPDF
2025-04-23Earnings deckPresentationPDF
2025-04-02Press releaseResmed to Report Third Quarter Fiscal 2025 Earnings on April 23, 2025
2025-01-30Earnings deckPresentationPDF
2025-01-30PresentationCorporate 1-PagerPDF
2025-01-30Press releaseResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025
2025-01-09Press releaseResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025
2024-10-24PresentationCorporate 1-PagerPDF
2024-10-24Earnings deckPresentationPDF
2024-10-03Press releaseResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 2024
2024-09-10Press releaseResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock Exchange
2024-08-01Earnings deckPresentationPDF
2024-08-01Press releaseResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024
2024-07-03Press releaseResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
2024-04-25Earnings deckPresentationPDF

RMD overview · RMD earnings · RMD financials · RMD KPIs · RMD ownership · RMD peers · RMD filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.